vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and YXT.COM GROUP HOLDING Ltd (YXT). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.1M, roughly 1.2× YXT.COM GROUP HOLDING Ltd).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

YXT.COM GROUP HOLDING Ltd is a leading digital learning solution provider operating primarily in the Chinese market. It offers corporate learning management systems, customized training content, and integrated talent development services for enterprise, educational institution and public sector clients across industries.

IRD vs YXT — Head-to-Head

Bigger by revenue
IRD
IRD
1.2× larger
IRD
$3.9M
$3.1M
YXT

Income Statement — Q4 FY2025 vs Q2 FY2024

Metric
IRD
IRD
YXT
YXT
Revenue
$3.9M
$3.1M
Net Profit
$405.6K
Gross Margin
61.1%
Operating Margin
-44.3%
Net Margin
12.9%
Revenue YoY
-10.2%
Net Profit YoY
53.0%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
YXT
YXT
Q4 25
$3.9M
Q3 25
$3.1M
Q2 25
$2.9M
Q1 25
$4.4M
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
$3.1M
Q1 24
$1.7M
Net Profit
IRD
IRD
YXT
YXT
Q4 25
Q3 25
$-17.5M
Q2 25
$-7.4M
Q1 25
$-8.2M
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
$405.6K
Q1 24
$-7.1M
Gross Margin
IRD
IRD
YXT
YXT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
61.1%
Q1 24
Operating Margin
IRD
IRD
YXT
YXT
Q4 25
Q3 25
-269.9%
Q2 25
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
-44.3%
Q1 24
-450.5%
Net Margin
IRD
IRD
YXT
YXT
Q4 25
Q3 25
-566.9%
Q2 25
-257.5%
Q1 25
-187.5%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
12.9%
Q1 24
-415.3%
EPS (diluted)
IRD
IRD
YXT
YXT
Q4 25
Q3 25
$-0.25
Q2 25
$-0.12
Q1 25
$-0.24
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
YXT
YXT
Cash + ST InvestmentsLiquidity on hand
$45.1M
$8.5M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$15.3M
Total Assets
$50.2M
$15.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
YXT
YXT
Q4 25
$45.1M
Q3 25
$30.8M
Q2 25
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
$8.5M
Q1 24
$47.2M
Total Debt
IRD
IRD
YXT
YXT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$2.3M
Q1 24
Stockholders' Equity
IRD
IRD
YXT
YXT
Q4 25
$15.3M
Q3 25
$6.0M
Q2 25
$17.5M
Q1 25
$5.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
IRD
IRD
YXT
YXT
Q4 25
$50.2M
Q3 25
$36.1M
Q2 25
$38.7M
Q1 25
$48.2M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M
$15.9M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
YXT
YXT
Operating Cash FlowLast quarter
$-35.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
YXT
YXT
Q4 25
$-35.3M
Q3 25
$-6.2M
Q2 25
$-10.3M
Q1 25
$-9.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons